{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:18:04Z","timestamp":1788430684800,"version":"build-2803163510"},"reference-count":26,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer Hispania S.L"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Metastatic androgen pathway modulation (mAPM)- sensitive prostate cancer, formerly termed metastatic hormone-sensitive prostate cancer, is a clinically heterogeneous disease in which treatment intensification decisions are guided by metastatic volume and timing of presentation. However, increasing use of advanced imaging and molecular profiling has revealed prognostic scenarios that are not adequately addressed by current algorithms. This study presents a structured multidisciplinary expert consensus exercise, rather than primary clinical research, applying the RAND\/UCLA Appropriateness Method to evaluate systemic treatment intensification strategies in mAPM-sensitive prostate cancer. Four anonymized real-world clinical cases representing key prognostic constellations \u2013 metachronous\/synchronous disease, low\/high metastatic burden \u2013 were assessed. Panellists rated the appropriateness of doublet therapy versus triplet therapy, including tailored \u2018what-if\u2019 variations, through two rounds of anonymous voting with structured discussion. The resulting assessments reflect structured expert judgement integrating available evidence with clinical experience. The panel identified metastatic pattern, particularly the presence and type of visceral involvement, disease dynamics, patient fitness and imaging context as dominant drivers of treatment selection. These findings should be interpreted as consensus-based appropriateness assessments rather than evidence-based treatment recommendations. They support a personalized, multidisciplinary approach to mAPM-sensitive prostate cancer management, emphasizing expert integration of prognostic factors beyond volume-based classifications in clinical scenarios where high-level evidence is limited or not directly applicable.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-multidisciplinary-expert-consensus-on-treatment-intensification-in-metastatic-androgen-pathway-modulation-sensitive-prostate-cancer-a-case-based-rand-ucla-analysis<\/jats:p>","DOI":"10.7573\/dic.2026-6-2","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:47:09Z","timestamp":1788428829000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Multidisciplinary expert consensus on treatment intensification in metastatic androgen pathway modulation-sensitive prostate cancer: a case-based RAND\/UCLA analysis"],"prefix":"10.7573","author":[{"given":"\u00c1ngel","family":"Borque-Fernando","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01r13mt55","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario Miguel Servet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/050eq1942","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario Ram\u00f3n y Cajal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Juan-Fita","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01fh9k283","id-type":"ROR","asserted-by":"publisher"}],"name":"Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lopez Campos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/050eq1942","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario Ram\u00f3n y Cajal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Adolfo","family":"P\u00e9rez-Fentes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00mpdg388","id-type":"ROR","asserted-by":"publisher"}],"name":"Complejo Hospitalario Universitario de Santiago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Vilaseca","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02a2kzf50","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Cl\u00ednic de Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Moretones Agut","sequence":"additional","affiliation":[{"name":"Bayer Hispania S.L"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Us\u00e1n","sequence":"additional","affiliation":[{"name":"Bayer Hispania S.L"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Maroto Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tSweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737\u2013746. https:\/\/doi.org\/10.1056\/NEJMoa1503747","DOI":"10.1056\/NEJMoa1503747"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tFizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u2013360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","DOI":"10.1056\/NEJMoa1704174"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tFrancini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone-sensitive prostate cancer. Prostate. 2018;78(12):889\u2013895. https:\/\/doi.org\/10.1002\/pros.23645","DOI":"10.1002\/pros.23645"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tMori K, Janisch F, Parizi MK, et al. Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(2):247\u2013257. https:\/\/doi.org\/10.1007\/s10147-019- 01578-9","DOI":"10.1007\/s10147-019-01578-9"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tNarita S, Nomura K, Hatakeyama S, et al. Prognostic significance of early changes in serum biomarkers in newly diagnosed metastatic prostate cancer. Sci Rep. 2019;9(1):12071. https:\/\/doi.org\/10.1038\/s41598-019-48600-8","DOI":"10.1038\/s41598-019-48600-8"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tCastro E, Romero-Laorden N, Del Pozo A, et al. PROREPAIR-B: impact of germline DNA-repair mutations in metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(6):490\u2013503. https:\/\/doi.org\/10.1200\/ JCO.18.00358","DOI":"10.1200\/JCO.18.00358"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tSwami U, Graf RP, Nussenzveig RH, et al. SPOP mutations as a predictive biomarker for androgen receptor\u2013 targeted therapy in de novo metastatic hormone-sensitive prostate cancer. Clin Cancer Res. 2022;28(22):4917\u2013 4925. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2228","DOI":"10.1158\/1078-0432.CCR-22-2228"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tMorris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL PET\/CT in men with biochemically recurrent prostate cancer: the CONDOR study. Clin Cancer Res. 2021;27(13):3674\u20133682. https:\/\/doi.org\/10.1158\/1078- 0432.CCR-20-4573","DOI":"10.1158\/1078-0432.CCR-20-4573"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tCombes AD, Palma CA, Calopedos R, et al. PSMA PET\/CT in the diagnosis and staging of prostate cancer. Diagnostics. 2022;12(11):2594. https:\/\/doi.org\/10.3390\/diagnostics12112594","DOI":"10.3390\/diagnostics12112594"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tHolzgreve A, Armstrong WR, Clark KJ, et al. PSMA PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw Open. 2025;8(1):e2452971. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.52971","DOI":"10.1001\/jamanetworkopen.2024.52971"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tUnterrainer LM, Hope TA, Fendler WP, et al. Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET \u2014 an international multicenter retrospective study. J Nucl Med. 2025;66(1):54\u201360. https:\/\/doi.org\/10.2967\/jnumed.124.268441","DOI":"10.2967\/jnumed.124.268441"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tSabahi Z, Papa N, Fendler WP, et al. Prognostic value of PSMA PET compared with CHAARTED criteria in an ENZAMET sub-cohort. J Clin Oncol. 2025;43(16 Suppl.):5091. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5091","DOI":"10.1200\/JCO.2025.43.16_suppl.5091"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tJadvar H, Calais J, Fanti S, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. 2022;63(1):59\u201368. https:\/\/doi.org\/10.2967\/jnumed.121.263262","DOI":"10.2967\/jnumed.121.263262"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tBorque-Fernando \u00c1, Alonso-Gordoa T, Juan-Fita MJ, et al. Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in metastatic hormone-sensitive prostate cancer. Future Oncol. 2025;21(8):991\u20131003. https:\/\/doi.org\/10.1080\/14796694.2025.2468569","DOI":"10.1080\/14796694.2025.2468569"},{"key":"ref14","unstructured":"15.\tNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459. Accessed December 29, 2025."},{"key":"ref15","unstructured":"16.\tCornford P, Tilki D, van den Bergh RCN, et al. EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG guidelines on prostate cancer. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf. Accessed December 29, 2025."},{"key":"ref16","unstructured":"17.\tFitch K, Bernstein SJ, Aguilar MD, et al. The RAND\/UCLA Appropriateness Method User\u2019s Manual. Santa Monica, CA: RAND Corporation; 2001. https:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html. Accessed December 29, 2025."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tBossi A, Foulon S, Maldonado X, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2024;404(10467):2065\u20132076. https:\/\/doi.org\/10.1016\/S0140-6736(24)01865-8","DOI":"10.1016\/S0140-6736(24)01865-8"},{"key":"ref18","unstructured":"19.\tParker CC, James ND, Brawley CD, et al. Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u20132366. https:\/\/ doi.org\/10.1016\/S0140-6736(18)32486-3"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tOlmos D, Lorente D, Jambrina A, et al. BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes. Ann Oncol. 2025;36(10):1190\u20131202. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.534","DOI":"10.1016\/j.annonc.2025.05.534"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tLozano R, Castro E, Lopez-Campos F, et al. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. Eur J Cancer. 2023;185:105\u2013118. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.022","DOI":"10.1016\/j.ejca.2023.02.022"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tRajwa P, Quhal F, Pradere B, et al. Prostate cancer risk, screening and management in patients with germline BRCA1\/2 mutations. Nat Rev Urol. 2023;20(4):205\u2013216. https:\/\/doi.org\/10.1038\/s41585-022-00680-4","DOI":"10.1038\/s41585-022-00680-4"},{"key":"ref22","unstructured":"23.\tCastro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748\u20131757. https:\/\/ doi.org\/10.1200\/JCO.2012.43.1882"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tAlabi BR, Zafar S, Landgraf M, et al. Current and emerging therapies for neuroendocrine prostate cancer. Trends Cancer. 2022;8(11):932\u2013945. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108255","DOI":"10.1016\/j.pharmthera.2022.108255"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tAttard G, Agarwal N, Graff JN, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med. 2025;31(12):4109\u20134118. https:\/\/doi.org\/10.1038\/s41591-025-03961-8","DOI":"10.1038\/s41591-025-03961-8"},{"key":"ref25","unstructured":"26.\tFizazi K, Clarke NW, De Santis M, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026;37(1):53\u201368. https:\/\/doi.org\/10.1016\/ j.annonc.2025.10.004"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/09\/dic.2026-6-2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:47:13Z","timestamp":1788428833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/multidisciplinary-expert-consensus-on-treatment-intensification-in-metastatic-androgen-pathway-modulation-sensitive-prostate-cancer-a-case-based-rand-ucla-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-6-2","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"dic.2026-6-2"}}